

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer - Fired NCI employee says Trump’s purge was baseless yet punitive
“I feel like I’ve been erased” - Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Pushing for tax cuts, Trump threatens the federal workforce, Medicaid, and cancer research
- “The Agency finds you are not fit…”
HHS notifications of firing add insult to injury